Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching

Background: Nirmatrelvir/ritonavir and azvudine have been approved for the early treatment of COVID-19 in China, however, limited real-world data exists regarding their effectiveness and safety. Methods: We conducted a retrospective cohort study involving the hospitalized COVID-19 patients in China...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, An-Hua, Zeng, Lu, Wang, Lu, Gui, Lin, Zhang, Wen-Ting, Gong, Xue-Peng, Li, Juan, Liu, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603265/
https://www.ncbi.nlm.nih.gov/pubmed/37900159
http://dx.doi.org/10.3389/fphar.2023.1274294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603265/
https://www.ncbi.nlm.nih.gov/pubmed/37900159
http://dx.doi.org/10.3389/fphar.2023.1274294

Ejemplares similares